Gabapentin Enacarbil Patent Expiration
Gabapentin Enacarbil is used for managing postherpetic neuralgia in adults and treating moderate-to-severe primary restless leg syndrome in adults. It was first introduced by Azurity Pharmaceuticals Inc
Gabapentin Enacarbil Patents
Given below is the list of patents protecting Gabapentin Enacarbil, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Horizant | US8795725 | GABA analog prodrug sustained release oral dosage forms | Jun 10, 2029 | Azurity |
| Horizant | US8026279 | Crystalline form of γ-aminobutyric acid analog | Nov 10, 2026 | Azurity |
| Horizant | US8114909 | Treating or preventing restless legs syndrome using prodrugs of GABA analogs | Apr 11, 2026 | Azurity |
| Horizant | US6818787 | Prodrugs of GABA analogs, compositions and uses thereof | Apr 06, 2025 | Azurity |
| Horizant | US8686034 | Crystalline form of γ-aminobutyric acid analog | Jan 24, 2025 | Azurity |
| Horizant | US8048917 | Prodrugs of GABA analogs, compositions and uses thereof |
Nov 06, 2022
(Expired) | Azurity |
Gabapentin Enacarbil's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List